OPKO’S GeneDx Extends Relationship with University of California Health for Genetic and Molecular Testing
June 07 2017 - 8:00AM
OPKO Health, Inc. (Nasdaq:OPK) announced today that GeneDx, a
business unit of OPKO’s BioReference Laboratories division,
extended its relationship with the University of California Health
(UC Health) for genetic, genomic, and molecular testing services.
UC Health, one of the nation’s leaders in genomics and precision
medicine in both the clinical and investigational arenas, has
selected GeneDx to supplement UC Health’s own robust offering of
genetic, genomic, and molecular testing services. By
having access to the latest in next generation genetics and
molecular oncology resources, both internally and externally, UC
Health remains at the forefront of precision medicine. OPKO’s
GeneDx is a leading commercial genetics laboratory in the United
States, while OPKO’s GenPath Oncology division was among the first
in the nation to focus on the molecular understanding of cancer.
“The foundation of precision medicine is precision diagnostics,
and through this relationship with OPKO’s GeneDx, our customers at
UC Health will not just better understand disease, but will close
the gap between data and diagnosis to help ensure good outcomes for
individuals and their communities,” said Gregory S. Henderson, MD,
PhD, President of BioReference Laboratories. “UC Health
already provides some of the best thinking in the country on the
use of diagnostic tools in clinical genomics and precision
medicine. Whole Exome Sequencing and other clinical services
offered by GeneDx will give UC Health’s world class doctors,
genetic counselors and other clinicians actionable insight into
some of the most pressing health challenges faced by their patients
and could expand the potential for their research to produce good
outcomes.”
GeneDx offers UC Health unique tools for understanding cancer,
rare diseases, prenatal conditions, and some of the most difficult
problems in medical diagnosis through a comprehensive menu of
genetic and genomic tests that will supplement UC Health’s testing
infrastructure across its medical centers at the UC Health
campuses. An important differentiator is GeneDx’s advanced analytic
tools, which not only provide the highest level of genetic testing,
but also the technology to add insight to the findings. GeneDx has
developed a unique, clinician focused population health tool
that allows end users to better manage and track their data at a
cohort or individual level in a protected and compliant manner.
About the University of CaliforniaFounded in
1868, the University of California is a public university
system that is considered the most comprehensive and advanced
postsecondary educational system in the world. UC comprises
ten college campuses and five medical centers with more than
238,000 students. For more information, visit
https://www.universityofcalifornia.edu/uc-system.
About GeneDxGeneDx is a world leader in
genomics with an acknowledged expertise in rare and ultra rare
genetic disorders, as well as one of the broadest menus of
sequencing services available among commercial laboratories.
Providing testing to patients and their families in more than 55
countries, GeneDx is a business unit of BioReference Laboratories,
a wholly owned subsidiary of OPKO Health, Inc. To learn more,
please visit www.genedx.com.
About OPKO Health, Inc. OPKO Health is a
diversified healthcare company that seeks to establish industry
leading positions in large, rapidly growing markets. Our
diagnostics business includes Bio-Reference Laboratories, the
nation's third-largest clinical laboratory with a core genetic
testing business and a 400-person sales and marketing team to drive
growth and leverage new products, including the 4Kscore® prostate
cancer test and the Claros® 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA-approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (launched in November 2016), VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched
by partner TESARO and IV formulation pending FDA approval),
OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes
and obesity which is a clinically advanced drug candidate among the
new class of GLP-1 glucagon receptor dual agonists, OPK88004, a
SARM (Selective Androgen Receptor Modulator) for treating BPH
(Benign Prostatic Hypertrophy), OPK88002, a NK-1 antagonist to
treat pruritus ( itching) in dialysis patients, and OPK88001, a
proprietary oligonucleotide to treat Dravet syndrome. In addition,
the Company is advancing its CTP technology, which includes long
acting hGH-CTP, a once weekly human growth hormone injection (in
phase 3 and partnered with Pfizer), and long acting Factor VIIa
drug for hemophilia in phase 2a. OPKO also has production and
distribution assets worldwide, multiple strategic investments and
an active business development strategy. More information available
at www.opko.com.
SAFE HARBOR STATEMENT
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding the
expected expansion of our relationship with the University of
California Health (UC Health) for genetic, genomic, and molecular
testing services, expected benefits from the relationship and the
ability to close the gap between data and diagnosis to help ensure
good outcomes for individuals, as well as other non-historical
statements about our expectations, beliefs or intentions regarding
our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors
include those described in our filings with the Securities and
Exchange Commission, as well as the risks inherent in funding,
developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments. In
addition, forward-looking statements may also be adversely affected
by general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
Contacts:
GeneDx
Victoria L. Laughman, 480-599-0954
vlaughman@genedx.com
Or
OPKO Health, Inc.
David Malina, 305-575-4137
DMalina@opko.com
Investor Relations
Or
Media
Rooney Partners
Terry Rooney, 212-223-0689
trooney@rooneyco.com
or
Marion Janic, 212-223-4017
mjanic@rooneyco.com
or
Investors
LHA Investor Relations
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024